ArticleSaudi journal of anaesthesia
A study of citrate and bivalirudin for anticoagulation during continuous renal replacement therapy in critically ill patients with acute kidney injury.
Article in Saudi journal of anaesthesia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During continuous renal replacement therapy (CRRT), regional citrate anticoagulation (RCA) and bivalirudin are appealing alternatives since they provide excellent anticoagulation within the circuit without increasing the risk of bleeding. This study has been done to assess the hemofilter survival time, length of intensive care unit (ICU) stays, bleeding, thrombosis, and kidney function in bivalirudin and RCA. Methods: A total of 40 patients who needed CRRT were enrolled in the study with acute kidney injury (AKI). The patients were divided into two groups of 20 each. RCA was used in the CRRT in the first group and bivalirudin in the second group according to protocol. We have monitored serum urea, serum creatinine, last 24 h urine output, hemoglobin (Hb), platelet count, prothrombin time (PT), international normalized ratio (INR), serum albumin, any bleeding complication, or any transfusion requirement pre-CRRT, during CRRT, and after CRRT. Results: Hemofilter life span was found significantly longer in the citrate group than the bivalirudin group (67.75 ± 16.64 vs 50.65 ± 7.98, Conclusion: After observing the data and statistical evaluation, we found that RCA has a better hemofilter life span than bivalirudin without a significant difference in mortality, bleeding, or transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.